By exploring an ensemble of feedback control immune designs, we quantified trade-offs between effective pathogen clearance and immunopathology. We identified genetic signal-processing perturbations that could improve efficacy while limiting toxicity of T-cell immunotherapies against cancer.

check out our manuscript (led by Obinna Ukogu) on Design principles of cytotoxic T-cell response: www.biorxiv.org/content/10.1...

Wanted to highlight our latest preprint--a huge effort by multiple people and labs, but led primarily by @wsdewitt.github.io, Tatsuya Araki, and Ashni Vora, in a very close wet-dry collaboration with @matsen.bsky.social’s lab at the Hutch

www.biorxiv.org/content/10.1...

Recasting the perils of phylodynamic non-identifiability as a feature not a bug, we show that a unique forward-equivalent process enables exact and efficient simulation from arbitrarily large populations. With M Celentano, S Prillo, @yun-s-song.bsky.social www.pnas.org/doi/10.1073/pnas.2412978122

this work was initiated by Mike Pun (now at Vant AI), and is built on his work on H-CNN: pnas.org/doi/10.1073/...

fantastic collaboration with @pgtimmune.bsky.social , @asya-minervina.bsky.social and Phil Bradley

check out our new manuscript (led by Gian Marco Visani):

structure-based machine learning model for TCR-pMHC complexes, predicting T-cell affinity to peptide-MHC complexes, quantifying T-cell receptor specificity, and designing de-novo immunogenic peptides:
arxiv.org/abs/2503.00648

yes please.

yes please.

would like to be added